99462-32-5 Usage
Uses
Used in Pharmaceutical Industry:
1,6-Dihydro-2-(hydroxyMethyl)-6-oxo-[3,4'-bipyridine]-5-carbonitrile is used as a key intermediate in the synthesis of 2-pyridone derivatives, which are known for their cardiotonic properties. These derivatives are used in the development of medications that help strengthen the contractions of the heart, improving its overall function and efficiency.
In the synthesis process, 1,6-Dihydro-2-(hydroxyMethyl)-6-oxo-[3,4'-bipyridine]-5-carbonitrile undergoes various chemical reactions to form the desired 2-pyridone derivatives. These derivatives exhibit positive inotropic effects, meaning they increase the force of heart muscle contractions without raising the intracellular levels of calcium. This makes them valuable in the treatment of heart failure and other conditions where the heart's pumping action is compromised.
Furthermore, the use of 1,6-Dihydro-2-(hydroxyMethyl)-6-oxo-[3,4'-bipyridine]-5-carbonitrile in the synthesis of cardiotonic agents allows for the development of more targeted and effective therapies. By understanding the specific mechanisms through which these compounds exert their effects, researchers can design medications that are more selective and less likely to cause adverse side effects.
Check Digit Verification of cas no
The CAS Registry Mumber 99462-32-5 includes 8 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 5 digits, 9,9,4,6 and 2 respectively; the second part has 2 digits, 3 and 2 respectively.
Calculate Digit Verification of CAS Registry Number 99462-32:
(7*9)+(6*9)+(5*4)+(4*6)+(3*2)+(2*3)+(1*2)=175
175 % 10 = 5
So 99462-32-5 is a valid CAS Registry Number.
99462-32-5Relevant academic research and scientific papers
NOVEL CHEMICAL AGENTS COMPRISING A CARDIOTONIC MOIETY AND AN IMAGING MOIETY AND METHODS OF THEIR USE
-
Page/Page column 25, (2008/06/13)
The present invention is directed to novel chemical agents for compounds and their use for imaging myocardial perfusion. The invention also is directed to a kit for forming such novel agents. The chemical agents for the present invention comprising (a) a cardiotonic moiety and (b) an imaging moiety.
